ClinicalTrials.gg
Sign In
Not yet recruitingNCT07873164VAMOSUpdated Oct 16, 2026

Vagal Auricular Stimulation for Motion Sickness

An interventional study of UROStim in Chronic Nausea, sponsored by Spaulding Rehabilitation Hospital. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Spaulding Rehabilitation Hospital · Not applicable, Interventional, and Other

Updated Oct 16, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study aims to understand the mechanisms underlying nausea response in the brain stem, and the effect of vagal nerve stimulation on nausea.

02

Conditions studied

  • Chronic Nausea

Keywords

  • Motion Sickness
  • Nausea
  • MRI
03

In context

Motion Sickness

50 studies on the registry are indexed under Motion Sickness; 9 are open to participants now.

This study's planned enrollment of 115 is above the median of 64 across 44 interventional studies indexed under Motion Sickness.

Browse Motion Sickness studies →

Lead sponsor

Spaulding Rehabilitation Hospital is the lead sponsor of 117 studies on the registry; 27 are open to participants now.

Of its 20 completed or terminated interventional studies of FDA-regulated products, 17 (85%) have results posted.

Browse Spaulding Rehabilitation Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years old (inclusive)
  • Ability to give written consent and participate in behavioral intervention in English
  • Avoidance of alcohol, nicotine, and caffeine for 24 hours prior to study session
  • Motion Sickness Susceptibility Questionnaire (MSSQ) percentile score > 60.
  • Adequate visual, hearing, cognitive, and physical ability

Exclusion criteria

Exclusion Criteria:

  • Chronic nausea due to medications or gastrointestinal conditions
  • Prior or current history of seizures
  • Severe autonomic dysfunction
  • No active clinical acupuncture therapy
  • History of arrhythmias
  • Endorses any contraindications to MRI
  • Body weight of 450 lbs or greater or BMI of 32 kg/m2 or greater (limit of MRI table)
  • History any serious medical condition (e.g., cancer)
  • Pregnancy/breastfeeding within the last 8 weeks
  • Uncontrolled diabetes (indicated by HbA1c ³ 7%) by chart
  • Narcotic analgesics greater than three days per week
  • Illicit drugs or opioid usage
  • Cannabinoid use greater than three days per week
  • Intellectual disability by history
  • Illiteracy
  • Inability to provide informed consent
  • Any other condition interfering with study requirements, according to the investigator
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    Visit 1: Active stimulation; Visit 2: Sham stimulation

    This group will receive active stimulation during the motion sickness paradigm of the first MRI, and sham stimulation during the motion sickness paradigm of the second MRI.

    Device: UROStim

  • Experimental
    Visit 1: Sham stimulation; Visit 2: Active Stimulation

    This group will receive sham stimulation during the motion sickness paradigm of the first MRI, and active stimulation during the motion sickness paradigm of the second MRI.

    Device: UROStim

Interventions

  • DeviceUROStim

    MRI safe vagal nerve stimulation during motion sickness inducing paradigm.

06

What researchers measure

Primary outcomes

  1. Simulator Sickness Questionnaire (SSQ), Nausea subscale

    0 (not at all) is the minimum, 3 (severe) is the maximum. Higher scores mean a worse outcome: a higher score means the participant reported more nausea symptoms.

    Time frame: 2 hours

07

Study locations

1 site
  • Spaulding Rehabilitation Hospital, 300 First Avenue
    Boston, Massachusetts 02129, United States
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2027; primary completion for Sep 2030, 36 months later.

Of 14 interventional studies with no phase under Motion Sickness, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 24. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2026
First posted
Oct 14, 2026
StartEst.
Sep 24, 2027
Primary completionEst.
Sep 24, 2030
CompletionEst.
Sep 24, 2031
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Also revised
eligibility and primary outcomes
Registered
First appeared on the registry
Oct 14, 2026
Show all 2 updates
  1. Oct 16, 2026
    Eligibility Criteria revised
    Primary outcomes Revised (1 change)
    + 1 other change: contact details
  2. Oct 14, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07873164
Lead sponsor
Spaulding Rehabilitation Hospital
Collaborators
National Center for Complementary and Integrative Health (NCCIH)
Responsible party
Roberta Sclocco (Assistant Professor of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital) — Principal investigator
First posted
Oct 14, 2026
Start date
Sep 24, 2027 (estimated)
Primary completion
Sep 24, 2030 (estimated)
Completion
Sep 24, 2031 (estimated)
Last update
Oct 16, 2026

Study contacts

Luca McKerley Coronado, BA
Contact
mghvamosstudy@mgb.org
(857) 238-0962

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Motion Sickness →

Other studies from this sponsor

Spaulding Rehabilitation Hospital →

Start the discussion